Share ownership VYNE Therapeutics Inc.

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
0.5700 ^USD	+2.33%		+1.86%	-1.74%

Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call

Share class: VYNE Therapeutics Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	14,751,433	13,512,520 ( 91.6 %)	0	91.6 %

Major shareholders: VYNE Therapeutics Inc.

Name	Equities	%	Valuation
Access Industries, Inc. (New York) 3.354 %	1,116,585	3.354 %	631 987 $
Nantahala Capital Management LLC 3.004 %	1,000,000	3.004 %	566 000 $
Baker Bros. Advisors LP 2.558 %	851,353	2.558 %	481 866 $
DSC Advisors LP 2.092 %	696,465	2.092 %	394 199 $
Acadian Asset Management LLC 1.918 %	638,492	1.918 %	361 386 $
Acorn Capital Advisors LLC 1.762 %	586,572	1.762 %	332 000 $
Shay Capital LLC 1.48 %	492,577	1.48 %	278 799 $
David Domzalski 1.25 %	416,208	1.25 %	235 574 $
Vanguard Fiduciary Trust Co. 0.945 %	314,545	0.945 %	178 032 $
Ikarian Capital LLC 0.8712 %	290,000	0.8712 %	164 140 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	21.24%
Individuals	2.47%
Other	0.4%
State Street Corp.	0.05%
Unknown	75.84%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	21.52%
Individuals	2.47%
United Kingdom	0.16%
Canada	0.01%

Based on 1000 largest holdings

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Employees

Sector

Biotechnology & Medical Research

Calendar

Feb. 25 - Q4 2025 Earnings Release (Projected)

More about the company